CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The CSL Ltd (ASX:CSL) share price is under the spotlight after reporting growth in its FY25 half-year result.
The best time to start investing is always now. Whether you’re new to shares or an experienced investor, here are 5 ETFs to consider in 2025.
Until 45, maximise your debt. After 45, maximise passive income.
Paul Clitheroe is interviewed by Owen Rask on The Australian Investors Podcast. See how Paul Clitheroe invests his money today.
The CSL Ltd (ASX:CSL) share price is in focus after the ASX healthcare share reported its FY24 result, with strong growth.
Are shares just gambling? Is the share market just a place for people with suits to gamble? Explainer of shares versus gambling.
The All Ordinaries (INDEXASX XAO) fell -2.08% on Friday, followed by a further -3.81% fall on Monday 5 August. What can you do?
The Commonwealth Bank of Australia (ASX: CBA) share price might be up 55% over 10 years. But how fast have CBA’s profits grown in that time?
So called “ethical investing” or ESG (environment, social, governance) investing has been one of the fastest growing sub-sectors over the last few years. Is this new fund the best way to invest ethically?
